A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer
Elevar Therapeutics
Elevar Therapeutics
Sun Yat-sen University
Sichuan Cancer Hospital and Research Institute
Fudan University
Shandong Cancer Hospital and Institute
Sichuan Cancer Hospital and Research Institute
Elevar Therapeutics
Jiangsu HengRui Medicine Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
Fudan University